Dr Reddys Laboratories shares see volume surge amid 0.69% rise

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

During today's session, Dr Reddys Laboratories witnessed a notable surge in trading volume, with the stock price increasing by 0.69% to Rs 1215.40. This increase has drawn attention to the stock's performance and market activity.

The increased volume and price movement position Dr Reddys Laboratories as a noteworthy stock within the Indian equity market. The company is included in key indices such as the NIFTY 50 and NIFTY 100, reflecting its significance in the broader market.

Financial Performance

Recent financial data provides insights into Dr Reddys Laboratories' performance.

Quarterly Highlights:

• Mar 2025: Revenue reached Rs 8,528.40 Cr, up from Rs 7,113.80 Cr in Mar 2024.
• Net Profit: Stood at Rs 1,581.20 Cr for Mar 2025, compared to Rs 1,306.30 Cr in Mar 2024.
• EPS: Reported as Rs 19.12 for Mar 2025.

Annual Overview:

• Revenue: Increased from Rs 19,047.50 Cr in 2021 to Rs 32,643.90 Cr in 2025.
• Net Profit: Rose from Rs 1,903.60 Cr in 2021 to Rs 5,703.50 Cr in 2025.
• EPS: Increased from Rs 117.67 in 2021 to Rs 64.22 in 2025.

Key Financial Ratios (Mar 2025):

• Debt to Equity: 0.12
• Return on Equity: 16.85%

The company's consistent revenue and profit growth, along with key financial ratios, highlight its financial stability.

Revenue Analysis

Dr Reddys Laboratories has demonstrated strong revenue growth over the past five years.

Net Profit Analysis

The net profit of Dr Reddys Laboratories has also shown significant growth.

Bearish Sentiment

According to a Moneycontrol analysis as of May 9, 2025, the sentiment for Dr Reddys Laboratories is bearish.

With the stock currently trading at Rs 1215.40, Dr Reddys Laboratories' performance reflects a combination of volume surge and marginal price increase amid bearish investor sentiment.